<DOC>
	<DOCNO>NCT00560274</DOCNO>
	<brief_summary>This single arm study assess safety NeoRecormon correction anemia patient chronic hepatitis C treat Pegylated interferon + ribavirin combination therapy . Patients receive NeoRecormon start dose 30,000 IU s.c. adjust require maintain target Hb 11-13g/dL . The anticipated time study treatment 1 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study NeoRecormon ( Epoetin Beta ) Anemic Patients With Chronic Hepatitis C .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic hepatitis C ; quantifiable serum HCV RNA ; Pegylated interferon + ribavirin treatment start &lt; 6 month study ; Hb &lt; 10g/dL . treatment ESA precede 12 week ; poorly control hypertension ; history cancer , except basal cell cancer cervical cancer situ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>